Jazz Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 1/6
Jazz Pharmaceuticals has a total shareholder equity of $3.7B and total debt of $5.7B, which brings its debt-to-equity ratio to 154.5%. Its total assets and total liabilities are $11.3B and $7.6B respectively. Jazz Pharmaceuticals's EBIT is $728.4M making its interest coverage ratio 2.6. It has cash and short-term investments of $1.8B.
Key information
154.5%
Debt to equity ratio
US$5.71b
Debt
| Interest coverage ratio | 2.6x |
| Cash | US$1.82b |
| Equity | US$3.70b |
| Total liabilities | US$7.63b |
| Total assets | US$11.33b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: J7Z's short term assets ($3.5B) exceed its short term liabilities ($1.6B).
Long Term Liabilities: J7Z's short term assets ($3.5B) do not cover its long term liabilities ($6.1B).
Debt to Equity History and Analysis
Debt Level: J7Z's net debt to equity ratio (105.2%) is considered high.
Reducing Debt: J7Z's debt to equity ratio has increased from 58.5% to 154.5% over the past 5 years.
Debt Coverage: J7Z's debt is not well covered by operating cash flow (18.2%).
Interest Coverage: J7Z's interest payments on its debt are not well covered by EBIT (2.6x coverage).